SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (SAVE-ICU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04415060|
Recruitment Status : Not yet recruiting
First Posted : June 4, 2020
Last Update Posted : June 26, 2020
Around1 in 4 COVID-19 patients suffer lung failure needing life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible by using drugs given through a vein. Unfortunately, these drugs are in short supply worldwide due to the high number of COVID-19 patients needing these machines.
Another way to provide sleep is by using gases that are breathed in. These are used every day in operating rooms to perform surgery. These gases, also called "inhaled agents" can also be used in intensive care units and may have several important benefits for patients and the hospital. Research shows they may reduce swelling in the lung and increase oxygen levels, which allows patients to recover faster and reduce the time spent on a breathing machine. In turn, this allows the breathing machine to be used again for the next sick patient. These drugs may also increase the number of patients who live through their illness. Inhaled agents are widely available and their use could dramatically lesson the pressure on limited drug supplies.
This research is a study being carried out in a number of hospitals that will compare how well patients recover from this illness depending on which type of sedation drug they receive. The plan is to evaluate the number who survive, their time spent on a breathing machine and time in the hospital. This study may show immediate benefits and may provide a cost effective and practical solution to the current challenges caring for patients and the hospital space, equipment and drugs to the greatest benefit. Finally, this trial will be a team of experts in sedation drugs who care for COVID-19 patients who need lifesaving treatments.
|Condition or disease||Intervention/treatment||Phase|
|Covid19||Drug: Isoflurane Inhalant Product Drug: Sevoflurane inhalant product||Phase 3|
Multicentre open-label, pragmatic, randomized controlled trial and a parallel prospective (non-randomized) cohort study conducted in ICUs and ICU enabled environments caring in critically ill COVID-19 patients.
Participants will be adults who are mechanically ventilated with proven positive or possible COVID-19 disease. All centres will be required to randomize every available patient, as non-randomized participants can be entered into a parallel prospective cohort study to try to obtain the maximum amount of information available from the patients present to our ICUs.
There will be variable randomized ratios of 2:1 or 1:2 to either an intravenous based sedation arm or an inhaled volatile-based sedation arm. This randomization will be dependent on availability of sedative drugs for both arms. Patients who cannot be randomized (secondary to technical or resource issues in some areas of the hospital) will receive intravenous or inhaled sedation as able in their designated unit. Sedation will be administered according to standard sedation practice and in keeping with current guidelines.
Participants will remain within their sedation arms until the primary care team decides to stop sedation. Participants will be followed daily throughout their ICU stay for 30 days after enrollment and then at death or hospital discharge (whichever occurs first).
Clinical information during ICU stay will be obtained from the patient chart, electronic medical records, or hospital databases. Participants will be followed using a provincial or hospital healthcare database to obtain survival, and hospital-free days at 60 days, 90 days and 365 days after enrollment.
After hospital discharge, participants will be followed up at; 3 and 12 months to assess quality of life using the EQ-5D; and to assess disability using the WHODAS 2.0.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||752 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Multicentre open-label, pragmatic, randomized controlled trial and a parallel prospective (non-randomized) cohort study|
|Masking:||None (Open Label)|
|Official Title:||SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study|
|Estimated Study Start Date :||June 15, 2020|
|Estimated Primary Completion Date :||June 15, 2022|
|Estimated Study Completion Date :||June 15, 2022|
Experimental: Inhaled - volatile anesthetic
The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
Drug: Isoflurane Inhalant Product
Isoflurane will be administered using an inhalation device
Drug: Sevoflurane inhalant product
Sevoflurane will be administered using an inhalation device
No Intervention: Standard Care
The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
No Intervention: Non-randomized
In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
- Hospital Mortality [ Time Frame: 2 years ]Does the use of inhaled volatile anesthetic-based sedation regimen improve participant hospital mortality as compared to standard intravenous sedation regimen with a 10% difference between groups for 752 participants.
- Ventilator-Free Days [ Time Frame: 30 days ]Does the use of inhaled volatile anesthetic-based sedation regimen improve participant ventilation outcomes after 30 days post enrollment, as compared to standard intravenous sedation regimen for 200 participants
- ICU-Free Days [ Time Frame: 30 days ]Does the use of inhaled volatile anesthetic-based sedation regimen improve participant time spent in ICU, 30 days post enrollment, as compared to standard intravenous sedation regimen for 128 participants
- Participant Quality of Life at 3 and 12 months after discharge [ Time Frame: 365 days ]Does the use of inhaled volatile anesthetic-based sedation regimen improve participant quality of life outcomes at 3 and 12 months post discharge as compared to standard intravenous sedation regimen for 144 participants. The EQ-5D questionnaire will be completed at both time points
- Median Daily Oxygenation [ Time Frame: 3 days ]To evaluate participant median daily oxygenation (PaO2/FiO2) at 3 days post enrollment
- Adjunctive ARDS therapies [ Time Frame: 30 days ]To evaluate participant need for adjunctive ARDS therapies (prone, nitric oxide, paralysis, ECMO) during ICU stay
- Hospital-Free Days [ Time Frame: 60 days ]To evaluate the number of hospital-free days for participants, 60 days after enrollment
- Disability [ Time Frame: 365 days ]To evaluate participant disability at 3 and 12 months post discharge. The World Health Organization Disabiltity Assessment Score (WHODAS 2.0) will be completed at both timepoints. The scores assigned to each of the items - "none" (0), "mild" (1) "moderate" (2), "severe" (3) and "extreme" (4) - are summed. This method is referred to as simple scoring because the scores from each of the items are simply added up without recoding or collapsing of response categories; thus, there is no weighting of individual items.
- Cost Utility Analysis [ Time Frame: 365 days ]Quality of Life (QALY) assessment to be calculated using the EQ-5D, comparison costs at 3 and 12 months post discharge, costs associated with hospital stay, devices and sedative costs
- Cost Effectiveness Analysis [ Time Frame: 365 days ]Life Year Gained (LYG) to be calculated using the EQ-5D, total costs during hospitalization, and health care utilization for 1 year after discharge.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04415060
|Contact: Angela Jerath, MDemail@example.com|
|University of Alberta Hospital|
|Edmonton, Alberta, Canada, T6G 2B7|
|Contact: Oleksa Rewa, MD firstname.lastname@example.org|
|Principal Investigator: Oleksa Rewa, MD|
|London Health Sciences Centre - University Hospital|
|London, Ontario, Canada, N6A 5A5|
|Contact: Marat Slessarev, MD Marat.Slessarev@lhsc.on.ca|
|Principal Investigator: Marat Slessarev, MD|
|London Health Sciences Centre - Victoria Hospital|
|London, Ontario, Canada|
|Contact: Marat Slessarev, MD Marat.Slessarev@lhsc.on.ca|
|Principal Investigator: Marat Slessarav, MD|
|Sub-Investigator: Claudio Martin, MD|
|Sunnybrook Health Sciences Centre|
|Toronto, Ontario, Canada, M4N3M5|
|Contact: Angela Jerath, MD 416.480.6100 email@example.com|
|Sub-Investigator: Brian Cuthbertson, MD|
|Principal Investigator: Angela Jerath, MD|
|University Health Network - Toronto General Hospital|
|Toronto, Ontario, Canada, M5G 2C4|
|Contact: Lorenzo del Sorbo, MD Lorenzo.delSorbo@uhn.ca|
|Centre hospitalier de l'Université de Montréal|
|Montréal, Quebec, Canada, H2X 3E4|
|Contact: Francois-Martin Carrier, MD firstname.lastname@example.org|
|Principal Investigator: Francois-Martin Carrier, MD|
|Universite de Sherbrooke|
|Sherbrooke, Quebec, Canada, J1K 2R1|
|Contact: Francois Lamontange, MD Francois.Lamontagne@USherbrooke.ca|
|Principal Investigator: Francois Lamontange, MD|
|University Health Network - Toronto Western Hopsital|
|Toronto, Canada, M5T 2S8|
|Contact: Ian Randall, MD email@example.com|